MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jgar.2025.02.014

Медицинская библиотека · Journal of global antimicrobial resistance · 2025

Second-line drug resistance among multidrug-resistant tuberculosis patients in Ethiopia: A laboratory-based surveillance.

Diriba Getu, Alemu Ayinalem, Yenew Bazezew, Ayano Betselot Zerihun, Hailu Michael, Buta Bedo, Wondimu Amanuel, Tefera Zigba, Meaza Abyot, Seid Getachew, Getahun Muluwork, Dagne Biniyam, Mollalign Hilina, Abebaw Yeshiwork, Getu Melak, Tadesse Mengistu, Belhu Tegegn, Alemu Ephrem, Demissie Minilik, Erresso Ashenafi, Aga Getachew, Kumsa Andargachew, Letta Taye, Abdella Saro, Moga Shewki, Dangisso Mesay Hailu, Tollera Getachew, Tadesse Gemechu

СтатьяПеревод в очереди

Аннотация

OBJECTIVES

To estimate the proportion of second-line anti-tuberculosis drug resistance among multidrug-resistant tuberculosis (MDR-TB) patients in Ethiopia.

METHODOLOGY: A laboratory-based prospective cross-sectional study was conducted at the National Tuberculosis Reference Laboratory (NTRL), Ethiopia, from February 2022 to July 2024. Phenotypic drug susceptibility testing (pDST) assessed resistance to various second-line antituberculosis drugs. The collected data were entered into Microsoft Excel 2016 and imported into Statistical Package for Social Sciences (SPSS) version 23 for descriptive analysis.

RESULT: Of 468 MDR-TB patients, 262 were new, and 206 were previously treated cases. Pre-extensively drug-resistant tuberculosis (pre-XDR-TB) was identified in four (1.52%) new cases and seven (3.40%) previously treated cases. Extensively drug-resistant tuberculosis (XDR-TB) was detected in three (1.15%) new cases and two (0.97%) previously treated cases. Overall, 11 (2.35%) cases were classified as pre-XDR-TB, and five (1.07%) as XDR-TB. Combined resistance to fluoroquinolones (FQs) and bedaquiline were detected in four cases (0.85%), comprising three new cases (1.15%) and one previously treated case (0.49%). Resistance to both FQs and linezolid was detected in a single previously treated case (0.49%) and acquired resistance to second-line drugs was identified in four cases.

CONCLUSIONS

Our study showed a prevalence of 2.35% for pre-XDR-TB and 1.07% for XDR-TB among MDR-TB cases, highlighting the importance of continuous surveillance and tailored treatment approaches to control the spread of drug-resistant TB (DR-TB) in Ethiopia. Future studies on MDR-TB surveillance should prioritize the integration of genomic surveillance into routine laboratory-based DR-TB monitoring systems to enhance early detection of resistance patterns, support targeted treatment strategies, and improve overall patient management efforts.

Для цитирования: Diriba Getu, Alemu Ayinalem, Yenew Bazezew, Ayano Betselot Zerihun, Hailu Michael, Buta Bedo, Wondimu Amanuel, Tefera Zigba, Meaza Abyot, Seid Getachew, Getahun Muluwork, Dagne Biniyam, Mollalign Hilina, Abebaw Yeshiwork, Getu Melak, Tadesse Mengistu, Belhu Tegegn, Alemu Ephrem, Demissie Minilik, Erresso Ashenafi, Aga Getachew, Kumsa Andargachew, Letta Taye, Abdella Saro, Moga Shewki, Dangisso Mesay Hailu, Tollera Getachew, Tadesse Gemechu. Second-line drug resistance among multidrug-resistant tuberculosis patients in Ethiopia: A laboratory-based surveillance.. Journal of global antimicrobial resistance. 2025. DOI: 10.1016/j.jgar.2025.02.014.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.